Kura Oncology

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Here is how Kura Oncology (KURA) and UnitedHealth Group (UNH) have performed compared to their sector so far this year.

Is Kura Oncology (KURA) Stock Outpacing Its Medical Peers This Year?

The average of price targets set by Wall Street analysts indicates a potential upside of 115.6% in Kura Oncology (KURA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Kura Oncology (KURA) Could Surge 116%: Read This Before Placing a Bet

Kura Oncology, Inc. (NASDAQ:KURA ) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ET Corporate Participants Pete De Spain - Senior Vice President of Investor Relations Troy Wilson - President and Chief Executive Officer Tom Doyle - Senior Vice President of Finance and Accounting Conference Call Participants Jonathan Chang - SVB Securities Peter Lawson - Barclays Roger Song - Jefferies Li Watsek - Cantor Fitzgerald Tiago Fauth - Credit Suisse Phil Nadeau - Cowen Reni Benjamin - JMP Securities Operator Ladies and gentlemen, please stand by. Good day and welcome to the Kara Oncology Third Quarter 2022 Earnings Conference Call.

Kura Oncology, Inc. (KURA) Q3 2022 Earnings Call Transcript

Here is how Kura Oncology (KURA) and Neurocrine Biosciences (NBIX) have performed compared to their sector so far this year.

Is Kura Oncology (KURA) Outperforming Other Medical Stocks This Year?

Abstract featuring updated data from KOMET-001 trial of ziftomenib accepted for oral presentation on December 10, 2022 Abstract featuring updated data from KOMET-001 trial of ziftomenib accepted for oral presentation on December 10, 2022

Kura Oncology Announces Four Abstracts Accepted for Presentation at ASH Annual Meeting

– Abstract reporting updated data from KOMET-001 accepted for oral presentation at ASH –

Kura Oncology Reports Third Quarter 2022 Financial Results

SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report third quarter 2022 financial results before U.S. financial markets open on Thursday, November 3, 2022. Kura's management will host a webcast and conference call at 8:00 a.m. ET / 5:00 a.m. PT that day to discuss the financial results and provide a corporate update.

Kura Oncology to Report Third Quarter 2022 Financial Results

– First demonstration that precision combination therapies can achieve a durable clinical response in PIK3CA-dependent HNSCC –

Kura Oncology Reports Preliminary Proof of Mechanism in Phase 1/2 Clinical Trial of Tipifarnib Plus Alpelisib in Head and Neck Squamous Cell Carcinoma

SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in the H.C. Wainwright 24th Annual Global Investment Conference. A pre-recorded presentation will be available to view on-demand beginning at 7:00 a.m. ET / 4:00 a.m. PT on September 12, 2022.

Kura Oncology to Participate in H.C. Wainwright Global Investment Conference

Kura Oncology, Inc. (NASDAQ:KURA ) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants Pete De Spain - Senior Vice President of Investor Relations Troy Wilson - President and Chief Executive Officer Tom Doyle - Senior Vice President of Finance and Accounting Conference Call Participants Jonathan Chang - SVB Securities Tiago Fauth - Credit Suisse Peter Lawson - Barclays Roger Song - Jefferies Li Watsek - Cantor Fitzgerald Reni Benjamin - JMP Securities Eva Privitera - Cowen, Inc. Operator Good day, and welcome to the Kura Oncology Second Quarter 2022 Conference Call. Today's conference is being recorded.

Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q2 2022 Results - Earnings Call Transcript

Adicet Bio, Inc.

IVERIC bio Inc

Chinook Therapeutics

 Pliant Therapeutics

Rocket Pharma

Caribou Biosciences

Biopharmaceutical companies have been struggling since 2021 and that narrative isn't immediately changing. However, not every firm deserves this fate.

7 Cheap Biotech Stocks to Buy Now

– Recommended Phase 2 dose for ziftomenib identified, pending FDA review –

Kura Oncology Reports Second Quarter 2022 Financial Results

SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Wedbush PacGrow Healthcare Virtual Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a panel titled “Bullseye - Targeted Oncology – In with the New” at 10:20 a.m. ET / 7:20 a.m. PT on Tuesday, August 9, 2022.

Kura Oncology to Participate in Wedbush PacGrow Healthcare Virtual Conference

SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report second quarter 2022 financial results after the close of U.S. financial markets on Wednesday, August 3, 2022. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.

Kura Oncology to Report Second Quarter 2022 Financial Results

Kura's Phase 1b data for menin inhibitor Ziftomenib in treating NPM1 mutant and KMT2A rearranged acute myeloid leukemia, or AML, is expected this quarter. Prior data showed a complete remission in a NPM1 mutant AML patient who had failed 7 prior lines of treatment.

Kura Oncology: Targeting NPM1 Mutations In Acute Myeloid Leukemia

Credit Suisse has raised the price target on Kura Oncology Inc (NASDAQ: KURA) to $29 from $27. The analysts say that evidence of an effective and tolerable agent and a clear recommended phase 2 dose for ziftomenib should support an upside of ~$8-10/share to their NPV.

Read Why Did Credit Suisse Raise Price Target On Kura Oncology

SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in three upcoming investor conferences:

Kura Oncology to Participate in Three Upcoming Investor Conferences

Kura Oncology, Inc. (NASDAQ:KURA ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Troy Wilson – Chairman and Chief Executive Officer Tom Doyle – Senior Vice President, Finance and Accounting Pete De Spain – Senior Vice President, Investor Relations and Corporate Communications Conference Call Participants Jonathan Chang – SVB Securities Peter Lawson – Barclays Corporate & Investment Bank Jonathan Ofertiago – Credit Suisse Roger Song – Jefferies Reni Benjamin – JMP Securities Eva Privitera – Cowen, Inc. Operator Good day and welcome to the Kura Oncology First-Quarter 2022 Earnings Conference Call. All participants will be in listen-only mode.

Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q1 2022 Results - Earnings Call Transcript

– Enrollment completed in Phase 1b expansion cohorts for ziftomenib; topline data expected in third quarter, full data presentation in fourth quarter –

Kura Oncology Reports First Quarter 2022 Financial Results

SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report first quarter 2022 financial results after the close of U.S. financial markets on Wednesday, May 4, 2022. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.

Kura Oncology to Report First Quarter 2022 Financial Results

– Late-breaking presentation at AACR demonstrates potential to significantly delay onset of drug resistance to EGFR-targeted therapies through combination with a farnesyl transferase inhibitor –

Kura Oncology Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergence of Resistance to Osimertinib in Non-Small Cell Lung Cancer

– Presentations to highlight significant opportunities targeting farnesyl transferase inhibition – – Presentations to highlight significant opportunities targeting farnesyl transferase inhibition –

Kura Oncology Announces Multiple Abstracts Accepted for Presentation at AACR Annual Meeting

Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q4 2021 Results - Earnings Call Transcript

– Patient enrollment continues in KOMET-001 Phase 1b study of ziftomenib (KO-539) in AML –

Kura Oncology Reports Fourth Quarter and Full Year 2021 Financial Results

SAN DIEGO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2021 financial results after the close of U.S. financial markets on Thursday, February 24, 2022. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.

News for Kura Oncology Stock (KURA)